Do analysts rate SPRO or TLRY?

Tilray Brands has a consensus target price of $11.50, suggesting a potential upside of 130.92%. Given Tilray Brands' stronger consensus rating and higher possible upside, analysts clearly believe Tilray Brands is more favorable than Spero Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Spero Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Tilray Brands 1 Sell rating(s) 4 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.25

Does the media prefer SPRO or TLRY?

In the previous week, Tilray Brands had 18 more articles in the media than Spero Therapeutics. MarketBeat recorded 20 mentions for Tilray Brands and 2 mentions for Spero Therapeutics. Spero Therapeutics' average media sentiment score of 1.42 beat Tilray Brands' score of 0.54 indicating that Spero Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spero Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tilray Brands 5 Very Positive mention(s) 5 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend SPRO or RLMD?

Relmada Therapeutics has a consensus price target of $12.00, suggesting a potential upside of 80.45%. Given Relmada Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Relmada Therapeutics is more favorable than Spero Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Spero Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Relmada Therapeutics 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.71

Does the media refer more to SPRO or RLMD?

In the previous week, Relmada Therapeutics had 1 more articles in the media than Spero Therapeutics. MarketBeat recorded 3 mentions for Relmada Therapeutics and 2 mentions for Spero Therapeutics. Spero Therapeutics' average media sentiment score of 1.42 beat Relmada Therapeutics' score of 0.63 indicating that Spero Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spero Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Relmada Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer ACRS or SPRO?

Aclaris Therapeutics currently has a consensus target price of $11.50, suggesting a potential upside of 166.20%. Given Aclaris Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Aclaris Therapeutics is more favorable than Spero Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aclaris Therapeutics 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 3 Strong Buy rating(s) 3.13 Spero Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Does the media favor ACRS or SPRO?

In the previous week, Aclaris Therapeutics had 2 more articles in the media than Spero Therapeutics. MarketBeat recorded 4 mentions for Aclaris Therapeutics and 2 mentions for Spero Therapeutics. Spero Therapeutics' average media sentiment score of 1.42 beat Aclaris Therapeutics' score of 0.97 indicating that Spero Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aclaris Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Spero Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer CLYM or SPRO?

Climb Bio presently has a consensus price target of $21.73, indicating a potential upside of 89.92%. Given Climb Bio's stronger consensus rating and higher possible upside, equities analysts clearly believe Climb Bio is more favorable than Spero Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Climb Bio 1 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 3 Strong Buy rating(s) 3.07 Spero Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Does the media prefer CLYM or SPRO?

In the previous week, Climb Bio had 9 more articles in the media than Spero Therapeutics. MarketBeat recorded 11 mentions for Climb Bio and 2 mentions for Spero Therapeutics. Spero Therapeutics' average media sentiment score of 1.42 beat Climb Bio's score of 0.51 indicating that Spero Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Climb Bio 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Spero Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend GYRE or SPRO?

Gyre Therapeutics presently has a consensus target price of $17.00, suggesting a potential upside of 186.68%. Given Gyre Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Gyre Therapeutics is more favorable than Spero Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gyre Therapeutics 2 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.00 Spero Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Spero Therapeutics (SPRO) Competitors

$2.85 +0.15 (+5.56%)

Closing price 04:00 PM Eastern

Extended Trading

$2.84 -0.02 (-0.53%)

As of 07:22 PM Eastern

Compare

SPRO vs. TLRY, RLMD, ACRS, CLYM, and GYRE

Should you buy Spero Therapeutics stock or one of its competitors? MarketBeat compares Spero Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Spero Therapeutics include Tilray Brands (TLRY), Relmada Therapeutics (RLMD), Aclaris Therapeutics (ACRS), Climb Bio (CLYM), and Gyre Therapeutics (GYRE). These companies are all part of the "pharmaceutical products" industry.

How does Spero Therapeutics compare to Tilray Brands?

Spero Therapeutics (NASDAQ:SPRO) and Tilray Brands (NASDAQ:TLRY) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, risk, earnings, analyst recommendations and profitability.

Spero Therapeutics has a beta of 1.45, indicating that its stock price is 45% more volatile than the broader market. Comparatively, Tilray Brands has a beta of 1.88, indicating that its stock price is 88% more volatile than the broader market.

25.6% of Spero Therapeutics shares are held by institutional investors. Comparatively, 9.4% of Tilray Brands shares are held by institutional investors. 2.9% of Spero Therapeutics shares are held by company insiders. Comparatively, 0.8% of Tilray Brands shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Spero Therapeutics has a net margin of 24.90% compared to Tilray Brands' net margin of -156.51%. Spero Therapeutics' return on equity of 35.58% beat Tilray Brands' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spero Therapeutics	24.90%	35.58%	24.95%
Tilray Brands	-156.51%	-3.31%	-2.42%

Tilray Brands has a consensus target price of $11.50, suggesting a potential upside of 130.92%. Given Tilray Brands' stronger consensus rating and higher possible upside, analysts clearly believe Tilray Brands is more favorable than Spero Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spero Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Tilray Brands	1 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25

Spero Therapeutics has higher earnings, but lower revenue than Tilray Brands. Tilray Brands is trading at a lower price-to-earnings ratio than Spero Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spero Therapeutics	$66.80M	2.47	$8.57M	$0.24	11.88
Tilray Brands	$821.31M	0.71	-$2.19B	-$13.65	N/A

In the previous week, Tilray Brands had 18 more articles in the media than Spero Therapeutics. MarketBeat recorded 20 mentions for Tilray Brands and 2 mentions for Spero Therapeutics. Spero Therapeutics' average media sentiment score of 1.42 beat Tilray Brands' score of 0.54 indicating that Spero Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spero Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tilray Brands	5 Very Positive mention(s)	5 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Spero Therapeutics beats Tilray Brands on 10 of the 16 factors compared between the two stocks.

How does Spero Therapeutics compare to Relmada Therapeutics?

Spero Therapeutics (NASDAQ:SPRO) and Relmada Therapeutics (NASDAQ:RLMD) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation, media sentiment and analyst recommendations.

Spero Therapeutics has higher revenue and earnings than Relmada Therapeutics. Relmada Therapeutics is trading at a lower price-to-earnings ratio than Spero Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spero Therapeutics	$66.80M	2.47	$8.57M	$0.24	11.88
Relmada Therapeutics	N/A	N/A	-$57.38M	-$1.09	N/A

Spero Therapeutics has a beta of 1.45, suggesting that its stock price is 45% more volatile than the broader market. Comparatively, Relmada Therapeutics has a beta of 0.39, suggesting that its stock price is 61% less volatile than the broader market.

Relmada Therapeutics has a consensus price target of $12.00, suggesting a potential upside of 80.45%. Given Relmada Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Relmada Therapeutics is more favorable than Spero Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spero Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Relmada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

25.6% of Spero Therapeutics shares are owned by institutional investors. Comparatively, 45.2% of Relmada Therapeutics shares are owned by institutional investors. 2.9% of Spero Therapeutics shares are owned by insiders. Comparatively, 14.5% of Relmada Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Spero Therapeutics has a net margin of 24.90% compared to Relmada Therapeutics' net margin of 0.00%. Spero Therapeutics' return on equity of 35.58% beat Relmada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spero Therapeutics	24.90%	35.58%	24.95%
Relmada Therapeutics	N/A	-71.22%	-64.46%

In the previous week, Relmada Therapeutics had 1 more articles in the media than Spero Therapeutics. MarketBeat recorded 3 mentions for Relmada Therapeutics and 2 mentions for Spero Therapeutics. Spero Therapeutics' average media sentiment score of 1.42 beat Relmada Therapeutics' score of 0.63 indicating that Spero Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spero Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Relmada Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Spero Therapeutics beats Relmada Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Spero Therapeutics compare to Aclaris Therapeutics?

Aclaris Therapeutics (NASDAQ:ACRS) and Spero Therapeutics (NASDAQ:SPRO) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability.

Aclaris Therapeutics has a beta of 0.76, indicating that its share price is 24% less volatile than the broader market. Comparatively, Spero Therapeutics has a beta of 1.45, indicating that its share price is 45% more volatile than the broader market.

Spero Therapeutics has higher revenue and earnings than Aclaris Therapeutics. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than Spero Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aclaris Therapeutics	$7.83M	77.05	-$64.92M	-$0.56	N/A
Spero Therapeutics	$66.80M	2.47	$8.57M	$0.24	11.88

Spero Therapeutics has a net margin of 24.90% compared to Aclaris Therapeutics' net margin of -832.58%. Spero Therapeutics' return on equity of 35.58% beat Aclaris Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aclaris Therapeutics	-832.58%	-55.89%	-38.49%
Spero Therapeutics	24.90%	35.58%	24.95%

In the previous week, Aclaris Therapeutics had 2 more articles in the media than Spero Therapeutics. MarketBeat recorded 4 mentions for Aclaris Therapeutics and 2 mentions for Spero Therapeutics. Spero Therapeutics' average media sentiment score of 1.42 beat Aclaris Therapeutics' score of 0.97 indicating that Spero Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aclaris Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Spero Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

98.3% of Aclaris Therapeutics shares are held by institutional investors. Comparatively, 25.6% of Spero Therapeutics shares are held by institutional investors. 4.8% of Aclaris Therapeutics shares are held by insiders. Comparatively, 2.9% of Spero Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Aclaris Therapeutics currently has a consensus target price of $11.50, suggesting a potential upside of 166.20%. Given Aclaris Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Aclaris Therapeutics is more favorable than Spero Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aclaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13
Spero Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Summary

Spero Therapeutics beats Aclaris Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Spero Therapeutics compare to Climb Bio?

Climb Bio (NASDAQ:CLYM) and Spero Therapeutics (NASDAQ:SPRO) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, profitability, dividends, risk, media sentiment and institutional ownership.

Spero Therapeutics has higher revenue and earnings than Climb Bio. Climb Bio is trading at a lower price-to-earnings ratio than Spero Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Climb Bio	N/A	N/A	-$59.85M	-$0.78	N/A
Spero Therapeutics	$66.80M	2.47	$8.57M	$0.24	11.88

Climb Bio presently has a consensus price target of $21.73, indicating a potential upside of 89.92%. Given Climb Bio's stronger consensus rating and higher possible upside, equities analysts clearly believe Climb Bio is more favorable than Spero Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Climb Bio	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	3 Strong Buy rating(s)	3.07
Spero Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Spero Therapeutics has a net margin of 24.90% compared to Climb Bio's net margin of 0.00%. Spero Therapeutics' return on equity of 35.58% beat Climb Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Climb Bio	N/A	-31.45%	-30.39%
Spero Therapeutics	24.90%	35.58%	24.95%

In the previous week, Climb Bio had 9 more articles in the media than Spero Therapeutics. MarketBeat recorded 11 mentions for Climb Bio and 2 mentions for Spero Therapeutics. Spero Therapeutics' average media sentiment score of 1.42 beat Climb Bio's score of 0.51 indicating that Spero Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Climb Bio	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Spero Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Climb Bio has a beta of 0.09, meaning that its share price is 91% less volatile than the broader market. Comparatively, Spero Therapeutics has a beta of 1.45, meaning that its share price is 45% more volatile than the broader market.

69.8% of Climb Bio shares are held by institutional investors. Comparatively, 25.6% of Spero Therapeutics shares are held by institutional investors. 2.6% of Climb Bio shares are held by insiders. Comparatively, 2.9% of Spero Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Spero Therapeutics beats Climb Bio on 10 of the 16 factors compared between the two stocks.

How does Spero Therapeutics compare to Gyre Therapeutics?

Gyre Therapeutics (NASDAQ:GYRE) and Spero Therapeutics (NASDAQ:SPRO) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, dividends, profitability, earnings, analyst recommendations, risk and valuation.

Gyre Therapeutics has a beta of 1.9, suggesting that its stock price is 90% more volatile than the broader market. Comparatively, Spero Therapeutics has a beta of 1.45, suggesting that its stock price is 45% more volatile than the broader market.

Spero Therapeutics has a net margin of 24.90% compared to Gyre Therapeutics' net margin of -5.44%. Spero Therapeutics' return on equity of 35.58% beat Gyre Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gyre Therapeutics	-5.44%	3.13%	2.67%
Spero Therapeutics	24.90%	35.58%	24.95%

In the previous week, Spero Therapeutics had 1 more articles in the media than Gyre Therapeutics. MarketBeat recorded 2 mentions for Spero Therapeutics and 1 mentions for Gyre Therapeutics. Gyre Therapeutics' average media sentiment score of 1.89 beat Spero Therapeutics' score of 1.42 indicating that Gyre Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Gyre Therapeutics	Very Positive
Spero Therapeutics	Positive

24.0% of Gyre Therapeutics shares are held by institutional investors. Comparatively, 25.6% of Spero Therapeutics shares are held by institutional investors. 9.5% of Gyre Therapeutics shares are held by insiders. Comparatively, 2.9% of Spero Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Spero Therapeutics has lower revenue, but higher earnings than Gyre Therapeutics. Gyre Therapeutics is trading at a lower price-to-earnings ratio than Spero Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gyre Therapeutics	$116.59M	4.94	$5.03M	-$0.09	N/A
Spero Therapeutics	$66.80M	2.47	$8.57M	$0.24	11.88

Gyre Therapeutics presently has a consensus target price of $17.00, suggesting a potential upside of 186.68%. Given Gyre Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Gyre Therapeutics is more favorable than Spero Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gyre Therapeutics	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
Spero Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Summary

Gyre Therapeutics and Spero Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

Get Spero Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SPRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SPRO vs. The Competition

Export

Metric	Spero Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$156.33M	$3.39B	$6.75B	$12.02B
Dividend Yield	N/A	2.25%	2.66%	5.61%
P/E Ratio	11.88	19.48	24.04	24.43
Price / Sales	2.47	304.87	510.75	109.73
Price / Cash	17.75	124.89	44.01	55.64
Price / Book	2.71	8.32	10.66	6.79
Net Income	$8.57M	$23.89M	$3.56B	$337.66M
7 Day Performance	1.06%	0.94%	0.05%	2.08%
1 Month Performance	12.20%	-1.16%	0.37%	3.16%
1 Year Performance	-1.38%	41.51%	22.73%	27.78%

Spero Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SPRO Spero Therapeutics	1.6433 of 5 stars	$2.85 +5.6%	N/A	-3.6%	$156.33M	$66.80M	11.88	150	Positive News
TLRY Tilray Brands	3.5922 of 5 stars	$5.23 +3.9%	$11.50 +120.1%	+20.2%	$606.64M	$821.31M	N/A	2,842
RLMD Relmada Therapeutics	2.1287 of 5 stars	$5.78 +1.0%	$12.00 +107.6%	+750.6%	$606.26M	N/A	N/A	10	News Coverage
ACRS Aclaris Therapeutics	3.1065 of 5 stars	$4.30 -1.5%	$11.50 +167.8%	+178.3%	$599.70M	$7.83M	N/A	100
CLYM Climb Bio	3.775 of 5 stars	$10.45 -3.0%	$21.64 +107.1%	+765.9%	$596.71M	N/A	N/A	9	News Coverage Analyst Forecast High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SPRO) was last updated on 6/12/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Spero Therapeutics (SPRO) Competitors

SPRO vs. TLRY, RLMD, ACRS, CLYM, and GYRE

How does Spero Therapeutics compare to Tilray Brands?

Summary

How does Spero Therapeutics compare to Relmada Therapeutics?

Summary

How does Spero Therapeutics compare to Aclaris Therapeutics?

Summary

How does Spero Therapeutics compare to Climb Bio?

Summary

How does Spero Therapeutics compare to Gyre Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPRO vs. The Competition

Spero Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Spero Therapeutics (SPRO) Competitors

SPRO vs. TLRY, RLMD, ACRS, CLYM, and GYRE

How does Spero Therapeutics compare to Tilray Brands?

Which has more risk & volatility, SPRO or TLRY?

Do institutionals and insiders believe in SPRO or TLRY?

Is SPRO or TLRY more profitable?

Do analysts rate SPRO or TLRY?

Which has stronger valuation & earnings, SPRO or TLRY?

Does the media prefer SPRO or TLRY?

Summary

How does Spero Therapeutics compare to Relmada Therapeutics?

Which has stronger earnings & valuation, SPRO or RLMD?

Which has more risk & volatility, SPRO or RLMD?

Do analysts recommend SPRO or RLMD?

Do institutionals & insiders hold more shares of SPRO or RLMD?

Is SPRO or RLMD more profitable?

Does the media refer more to SPRO or RLMD?

Summary

How does Spero Therapeutics compare to Aclaris Therapeutics?

Which has more risk and volatility, ACRS or SPRO?

Which has stronger earnings & valuation, ACRS or SPRO?

Is ACRS or SPRO more profitable?

Does the media favor ACRS or SPRO?

Do institutionals and insiders hold more shares of ACRS or SPRO?

Do analysts prefer ACRS or SPRO?

Summary

How does Spero Therapeutics compare to Climb Bio?

Which has stronger earnings and valuation, CLYM or SPRO?

Do analysts prefer CLYM or SPRO?

Is CLYM or SPRO more profitable?

Does the media prefer CLYM or SPRO?

Which has more volatility & risk, CLYM or SPRO?

Do insiders & institutionals have more ownership in CLYM or SPRO?

Summary

How does Spero Therapeutics compare to Gyre Therapeutics?

Which has more volatility & risk, GYRE or SPRO?

Is GYRE or SPRO more profitable?

Does the media favor GYRE or SPRO?

Do insiders and institutionals believe in GYRE or SPRO?

Which has preferable earnings & valuation, GYRE or SPRO?

Do analysts recommend GYRE or SPRO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPRO vs. The Competition

Spero Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools